-
Mashup Score: 0
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Dr Rosenberg on Efforts to Enhance Urothelial Cancer Treatment - 4 hour(s) ago
Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma - 5 hour(s) ago
The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Identifying Individual Social Determinants of Health Could Reduce Barriers to Breast Cancer Care - 8 hour(s) ago
Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0OncLive’s April Roundup of Key FDA Decisions in Oncology - 9 hour(s) ago
In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Pirtobrutinib Transforms SOC in Later-Line CLL/SLL - 10 hour(s) ago
Jean L. Koff, MD, MS, highlights data for pirtobrutinib in pretreated CLL/SLL and how the agent altered later-line care for these patients.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Relatlimab Plus Nivolumab/Chemo Misses ORR End Point in LAG-3+ Advanced Gastric/GEJ Cancer - 11 hour(s) ago
Relatlimab plus nivolumab and chemotherapy did not improve responses in untreated advanced gastric or GEJ cancer with a LAG-3 expression of at least 1%.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Repotrectinib Receives NMPA Approval for ROS1+ NSCLC - 12 hour(s) ago
Repotrectinib has been approved by China’s National Medical Products Administration for the treatment of patients with ROS1-positive NSCLC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Avutometinib Plus Defactinib Signals Changing Tides in Low-Grade Serous Ovarian Cancer - 13 hour(s) ago
Jubilee Brown, MD, highlights the RAS/MAPK pathway in low-grade serous ovarian cancer and research with avutometinib/defactinib that prompted RAMP 301.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Grivas Spotlights Advances With Immunotherapy-Based Approaches in Urothelial Cancer @PGrivasMDPhD @fredhutch #blcsm https://t.co/BTjABtJ3Vd